566 related articles for article (PubMed ID: 22677045)
1. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
Krueger JG; Fretzin S; Suárez-Fariñas M; Haslett PA; Phipps KM; Cameron GS; McColm J; Katcherian A; Cueto I; White T; Banerjee S; Hoffman RW
J Allergy Clin Immunol; 2012 Jul; 130(1):145-54.e9. PubMed ID: 22677045
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
3. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
6. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
Johnston A; Fritz Y; Dawes SM; Diaconu D; Al-Attar PM; Guzman AM; Chen CS; Fu W; Gudjonsson JE; McCormick TS; Ward NL
J Immunol; 2013 Mar; 190(5):2252-62. PubMed ID: 23359500
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis.
Cheuk S; Wikén M; Blomqvist L; Nylén S; Talme T; Ståhle M; Eidsmo L
J Immunol; 2014 Apr; 192(7):3111-20. PubMed ID: 24610014
[TBL] [Abstract][Full Text] [Related]
9. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.
Singh TP; Schön MP; Wallbrecht K; Gruber-Wackernagel A; Wang XJ; Wolf P
PLoS One; 2013; 8(1):e51752. PubMed ID: 23335955
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
Azevedo A; Torres T
Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
12. The role of IL-17 in psoriasis.
Malakouti M; Brown GE; Wang E; Koo J; Levin EC
J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
[TBL] [Abstract][Full Text] [Related]
13. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
[TBL] [Abstract][Full Text] [Related]
14. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of IL-17A blockade in psoriasis.
Puig L; Carrascosa JM
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
[No Abstract] [Full Text] [Related]
16. Ixekizumab for treatment of psoriasis.
Dyring-Andersen B; Skov L; Zachariae C
Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
[TBL] [Abstract][Full Text] [Related]
17. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.
Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358
[TBL] [Abstract][Full Text] [Related]
18. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
19. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
20. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
